Bleomycin plasma spill-over levels in paediatric patients undergoing intralesional injection for the treatment of haemangiomas

South African Medical Journal

Volumn 98, Issue 7, 2008, Pages 539-540

  Ionescu, G ^a   Mabeta, Peace ^a   Dippenaar, N ^a   Muir, T ^a   Fourie, P ^b   Shelver, G ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Netcare Unitas Hospital   (South Africa)

^c Varian Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BLEOMYCIN SULFATE;

ADOLESCENT; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEMANGIOMA; HODGKIN DISEASE; HUMAN; INFANT; KAPOSI SARCOMA; LETTER; LUNG FIBROSIS; RISK REDUCTION;

AGE FACTORS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; FEMALE; HEMANGIOMA; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES;

EID: 48749124664     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Mulliken JB, Young AE. Hemangiomas and Malformations. Philadelphia: WB Saunders, 1988: 39-65.
2. Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg 2000; 106:529-537.
3. Kullendorf CM. Efficacy of bleomycin treatment for symptomatic hemangiomos in children. Pediatr Surg Int 1997; 12: 526-528.
4. Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for hemangiomas and congenital vascular malformations. Int J Pediatr Surg 2004; 19: 766-773.
5. James MP, Collier PM, Aherne W, Hardcastle A, Lovegrove S. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol 1993; 28: 933-937.
6. Dorr RT, Meyers R, Snead K, Liddil JD. Analytical and biological inequivalence of two commercial formulations of the antitumour agent bleomycin. Cancer Chemother Pharmacol 1998; 42: 149-154.